Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Archive
    • Upcoming Scientific Articles
  • Info for
    • Authors
    • Reviewers
    • Advertisers
    • Subscribers
  • About Us
    • About the North Carolina Medical Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Help
    • RSS
  • Other Publications
    • North Carolina Medical Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
North Carolina Medical Journal
  • Other Publications
    • North Carolina Medical Journal
  • My alerts
  • Log in
North Carolina Medical Journal

Advanced Search

  • Home
  • Content
    • Current
    • Archive
    • Upcoming Scientific Articles
  • Info for
    • Authors
    • Reviewers
    • Advertisers
    • Subscribers
  • About Us
    • About the North Carolina Medical Journal
    • Editorial Board
  • More
    • Alerts
    • Feedback
    • Help
    • RSS
  • Follow ncmj on Twitter
  • Visit ncmj on Facebook
Research ArticlePolicy Forum

SCID

A Pediatric Emergency

Rebecca H. Buckley
North Carolina Medical Journal January 2019, 80 (1) 55-56; DOI: https://doi.org/10.18043/ncm.80.1.55
Rebecca H. Buckley
J. Buren Sidbury professor of Pediatrics and professor of Immunology, Duke University Medical Center, Durham, North Carolina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rebecca.buckley@duke.edu
  • Article
  • References
  • Info & Metrics
  • PDF
Loading

Severe combined immunodeficiency (SCID) is a syndrome of diverse genetic cause characterized by an absence of T cells, resulting in a profound deficiency of adaptive immune function. This condition is uniformly fatal in the first two years of life unless immune reconstitution can be accomplished. Early recognition of SCID should be considered a pediatric emergency [1], because a diagnosis before live vaccines such as rotovirus [2, 4] or non-irradiated blood products are given and before the development of infections permits lifesaving hematopoietic stem cell transplantation [5-8], enzyme replacement therapy [9], or gene therapy [10-12]. However, most SCID infants appear physically normal at birth and until they begin to develop infections, then failure to thrive begins. In most cases, there is no family history of SCID. If SCID is not detected until the infant is older, there is a much higher likelihood that death will occur before successful definitive therapy can be achieved.

The need for newborn screening for this condition has been recognized for the past 21 years. However, implementation of screening required development of an assay for T cell lymphopenia that could be performed on dried blood spots that have been routinely collected from newborn infants for the past 54 years. This test development was accomplished eight years ago and shortly thereafter a recommendation was made to the US Department of Helath and Human Service Secretary's Advisory Committee on Heritable Disorders of Newborns and Children to add SCID and other forms of T cell lymphopenia to the routine newborn screening panel. This was approved unanimously by the Committee and then by the Secretary of Health and Human Services in 2010. Currently, all 50 states have added screening for SCID and other forms of T cell lymphopenia to their routine newborn screening panel.

The results of screening for T cell lymphopenia are reported to the primary care provider as either normal, abnormal, or borderline. If abnormal, the infant should see an immunologist within three days after having been seen by the primary care provider. If borderline, the physician will be asked to submit a second dried blood spot within 24 hours. In both cases, a set of instructions from the state newborn screening follow-up office will be sent to the physician regarding appropriate care of the infant while evaluations are being performed.

The infant should not be referred directly to a bone marrow transplant service because, as noted above, other non-SCID causes of T cell lymphopenia are detected by this screening test. A majority of these conditions will probably require different forms of treatment than those needed for SCID infants. This is the paramount reason that an immunologist is needed to determine the precise cause of the T cell lymphopenia and ultimately the appropriate treatment. Among the most frequent conditions other than SCID detected by this screening are DiGeorge syndrome (usually only the complete DiGeorge syndrome), ataxia telangiectasia, trisomy 21, CHARGE syndrome, congenital cardiac syndromes, other congenital anomalies, and vascular leakage syndromes. Many of the borderline and some of the abnormal results are due to prematurity. Abnormal and borderline results could also be due to technical problems such as drawing the blood for the dried blood spot through a heparinized central line or collecting it through a capillary tube.

In the past, a majority of the conditions screened for in newborn screening panels have been metabolic or endocrine disorders or hemoglobinopathies. With the availability of modern molecular technology, it is likely that in the future many other types of genetic diseases will be screened for and detected at birth.

SCID and other forms of T cell lymphopenia are the first group of genetically determined immunologic disorders to be screened for. There are now 354 recognized inborn errors of immunity and the abnormal genes are known for 344 of them [13]. All of these conditions would benefit from early diagnosis before life-threatening infections develop, so it is clear that detection at birth would be ideal.

Resistance by individual states to adapt the recommendations of the HHS Secretary's Advisory Committee for additions to the Routine Screening Panel is almost always due to cost issues. In most cases the implementation of screening actually saves the state money because it reduces costs for Medicaid and other third-party payors that provide treatment for infants and children with serious or life-threatening infections. Prevention of such infections is even more important because permanent and significant organ damage can occur from them even if the infant survives.

Acknowledgments

Potential conflicts of interest. R.H.B. has no relevant conflicts of interests

  • ©2019 by the North Carolina Institute of Medicine and The Duke Endowment. All rights reserved.

References

  1. ↵
    1. Buckley RH,
    2. Schiff RI,
    3. Schiff SE, et al.
    Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr. 1997;130(3):378-387.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Patel NC,
    2. Hertel PM,
    3. Estes MK, et al.
    Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med. 2010;362(4):314-319.
    OpenUrlCrossRefPubMed
    1. Werther RL,
    2. Crawford NW,
    3. Boniface K,
    4. Kirkwood CD,
    5. Smart JM
    Rotavirus vaccine induced diarrhea in a child with severe combined immune deficiency. J Allergy Clin Immunol. 2009;124(3):600.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Uygungil B,
    2. Bleesing JJ,
    3. Risma KA,
    4. McNeal MM,
    5. Rothenberg ME
    Persistent rotavirus vaccine shedding in a new case of severe combined immunodeficiency: A reason to screen. J Allergy Clin Immunol. 2010;125(1):270-271.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Buckley RH,
    2. Schiff SE,
    3. Schiff RI, et al.
    Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340(7):508-516.
    OpenUrlCrossRefPubMed
    1. Kane L,
    2. Gennery AR,
    3. Crooks BN,
    4. Flood TJ,
    5. Abinun M,
    6. Cant AJ
    Neonatal bone marrow transplantation for severe combined immunodeficiency. Arch Dis Child Fetal Neonatal Ed. 2001;85(2):F110-F113.
    OpenUrlAbstract/FREE Full Text
    1. Myers LA,
    2. Patel DD,
    3. Puck JM,
    4. Buckley RH
    Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99(3):872-878.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Buckley RH
    Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res. 2011;49(1-3):25-43.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Hershfield MS,
    2. Buckley RH,
    3. Greenberg ML, et al.
    Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987;316(10):589-596.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Aiuti A,
    2. Cattaneo F,
    3. Galimberti S, et al.
    Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447-458.
    OpenUrlCrossRefPubMed
    1. Hacein-Bey-Abina S,
    2. Hauer J,
    3. Lim A, et al.
    Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010;363(4):355-364.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Gaspar HB,
    2. Cooray S,
    3. Gilmour KC, et al.
    Long-term persistence of a polyclonal T cell repertoire after gene therapy for x-linked severe combined immunodeficiency. Sci Transl Med. 2011;3(97):97ra79.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Picard C,
    2. Bobby GH,
    3. Al-Herz W, et al.
    International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol. 2018;38(1):96-128.
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

North Carolina Medical Journal: 80 (1)
North Carolina Medical Journal
Vol. 80, Issue 1
January-February 2019
  • Table of Contents
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on North Carolina Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
SCID
(Your Name) has sent you a message from North Carolina Medical Journal
(Your Name) thought you would like to see the North Carolina Medical Journal web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 15 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
SCID
Rebecca H. Buckley
North Carolina Medical Journal Jan 2019, 80 (1) 55-56; DOI: 10.18043/ncm.80.1.55

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
SCID
Rebecca H. Buckley
North Carolina Medical Journal Jan 2019, 80 (1) 55-56; DOI: 10.18043/ncm.80.1.55
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Acknowledgments
    • References
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The Future of Newborn Screening: Why and How Partnerships Will Be Needed for Success
  • Google Scholar

More in this TOC Section

Policy Forum

  • A Vaccine for Society
  • Focus on Philanthropy : Investing in the Affordable Care Act and Expanding Medicaid are Critical to Statewide Health
  • Spotlight on the Safety Net : NC Get Covered – A Statewide Network of Health Care Change Agents
Show more Policy Forum

INVITED COMMENTARIES AND SIDEBARS

  • A Vaccine for Society
  • Focus on Philanthropy : Investing in the Affordable Care Act and Expanding Medicaid are Critical to Statewide Health
  • Spotlight on the Safety Net : NC Get Covered – A Statewide Network of Health Care Change Agents
Show more INVITED COMMENTARIES AND SIDEBARS

Similar Articles

About & Contact

  • About the NCMJ
  • Editorial Board
  • Feedback

Info for

  • Advertisers
  • Authors
  • Reviewers
  • Subscribers

Articles & Alerts

  • Archive
  • Current Issue
  • Get Alerts
  • Upcoming Articles

Additional Content

  • Current NCIOM Task Forces
  • NC Health Data & Resources
  • NCIOM Blog
North Carolina Medical Journal

ISSN: 0029-2559

© 2021 North Carolina Medical Journal

Powered by HighWire